Lakefront Biotherapeutics (LKFT) Other Non Operating Income (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has 12 years of Other Non Operating Income data on file, last reported at $17.2 million in Q4 2025.

• Other Non Operating Income for Q4 2025 came in at $17.2 million, down 8.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $73.6 million (down 24.02% YoY), and the FY2025 annual result was $52.6 million, down 44.92% from the prior year.
• Other Non Operating Income improved to $17.2 million in Q4 2025 per LKFT's latest filing, from $12.4 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $43.7 million in Q1 2021 and troughed at -$3.9 million in Q1 2022.
• A 5-year average of $18.8 million and a median of $20.6 million in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income sank 109.0% in 2022, then surged 2431.2% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at $43.7 million in 2021, then plunged by 71.73% to $12.3 million in 2022, then jumped by 105.69% to $25.4 million in 2023, then dropped by 25.51% to $18.9 million in 2024, then slipped by 8.92% to $17.2 million in 2025.
• Business Quant data shows LKFT's Other Non Operating Income at $17.2 million in Q4 2025, $12.4 million in Q1 2025, and $18.9 million in Q4 2024.